Pages
- About Us
- Advocacy Groups for Patients with Cancer
- Cancer Trial and Treatment Resources for Clinicians
- Contact Us
- Industry | Why Partner with Us
- News | Cancer Research and Innovation
- Newsletter sign up
- Our Programs
- ASPiRATION Lung Cancer Study
- Cancer Screening Program (CaSP)
- Companion Studies (C2)
- Company Studies (C3)
- Genetic Cancer Risk in the Young (RisC) study – Now closed
- Molecular Screening & Therapeutics (MoST) study
- MoST Core Studies (C1)
- MoST-LLy | Leukaemia & Lymphoma Subprogram
- SMOC+ (Multi-Organ Cancer Surveillance Study)
- Outsmarting Cancer, Together
- Patients & Families | Cancer Clinical Trials
- Privacy Policy
- Researchers | Why Work with Us
- Resources & Events
- Site Map
- Thank You
- The PrOSPeCT Program
News
- Merck joins forces with Omico to improve access to cancer trials in Australia
- Icon Cancer Centre, Omico Partner to Expand Access to Precision Oncology for Australians
- Federal Government Invests $30.8M to Advance Precision Oncology for Adults with Cancer Through ‘Precision Oncology Screening Platform Enabling Clinical Trials’ - PrOSPeCT
- World First Research Project Launched by Omico Australia to Advance Treatment of Sarcoma
- New Omico Podcast Empowers Australians to Navigate Precision Oncology and Genomic Innovation
- Omico Proposes a Transformative Solution for Affordable Precision Oncology as Routine Care for Rare Cancer
- Understanding Your Options in Cancer Care: Omico’s 2025 Genomics Education Events for Patients, Families, and Carers
- ASPiRATION Study: Collaborative Efforts Drive Exceptional Patient Follow-Up Data in Advancing Lung Cancer Research
- Professor David Thomas Receives NSW Premier’s Award for Outstanding Cancer Researcher of 2024: Award Honours Lifetime Contributions to Cancer Research and Advancing Precision Oncology as Standard Care
- Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers
- First of its kind educational cancer and genomics initiative commences for the community
- ‘No time to waste, no more lives to lose’ says genomics pioneer. A bold and innovative approach is needed to fight cancer
- Prof. David Thomas will Address the National Press Club of Australia
- Omico achieves major milestone!
- Update March 2024: Omico and PrOSPeCT
- Omico Working Together with Australian Cancer Patient Advocacy Groups
- Unlocking the Power of Real-World Data at Omico
- Omico’s National Clinical Trials Network
- Omico Strengthens Leadership Team for Sustainable Growth: Welcomes New Full-time CEO.
- PrOSPeCT formally launches, bringing new hope to Australians with incurable or advanced cancers
- 7,000 patients reached via MoST
- Ground-breaking Australian research answers long-standing genetic mystery of why people develop rare hidden cancer
- New hope secured for Australians with LFS
- 5,000 patients reached on MoST
- SPORE grant to investigate leiomyosarcoma
- A Current Affair feature on MoST
- World Cancer Research Day 2022
- Rare Cancers Australia podcast series
- Presenting with Foundation Medicine at ESMO 2022
- We have entered into a collaboration agreement with Oncoshot
- $185 million investment to fast-track treatments for rare and ‘untreatable’ cancers
- APOS 2021 - DNA & Beyond - online event
- Pancreatic cancer program
- 2020 Masterclass Publications and webinar recordings
- ASPiRATION study - first patient enrolled
- Making a difference
- Masterclass webinar series - Demystifying the Molecular Tumour Board
- How cancer develops resistance to treatment
- A reflection on cancer
- Australian Government & Roche co-fund the ‘ASPiRATION’ lung cancer study
- Access to clinical trials crucial for Australians living with rare or uncommon cancers
- Ground-breaking trial brings personalised treatments to those with rare cancers
- Ground breaking trial